Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of ...
Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised ...
Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...
Blackstone is raising a new life sciences fund, targeting at least $5B after initial $1.6B closing. Blackstone Life Sciences ...
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback